Last reviewed · How we verify
VIN
VIN (vinblastine) is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in rapidly dividing cells.
VIN (vinblastine) is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in rapidly dividing cells. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma, Testicular cancer.
At a glance
| Generic name | VIN |
|---|---|
| Also known as | Vincristine |
| Sponsor | Italian Sarcoma Group |
| Drug class | Vinca alkaloid; microtubule inhibitor |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vinblastine binds to β-tubulin and prevents microtubule polymerization, which arrests cells in metaphase of mitosis. This leads to cell cycle arrest and programmed cell death in cancer cells. It is a classic chemotherapy agent with activity across multiple malignancies, particularly lymphomas and solid tumors.
Approved indications
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Testicular cancer
- Breast cancer
- Lung cancer
- Sarcoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Alopecia
- Constipation
Key clinical trials
- CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision (NA)
- A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia (NA)
- Vinpocetine in Patients With Parkinsonian Disease (PHASE2, PHASE3)
- NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer (NA)
- Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia (PHASE2)
- Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIN CI brief — competitive landscape report
- VIN updates RSS · CI watch RSS
- Italian Sarcoma Group portfolio CI